Cetrelimab (Synonyms: JNJ 63723283; JNJ 3283) |
| Catalog No.GC68857 |
Cetrelimab (JNJ 63723283; JNJ 3283) es un anticuerpo monoclonal humanizado IgG4κ dirigido contra PD-1. Cetrelimab se une a PD-1 con una Kd de 1,72 nM (células HEK293). Por lo tanto, Cetrelimab bloquea la interacción entre PD-1 y PD-L1 y PD-L2 (IC50 de 111,7 ng/mL y 138,6 ng/mL respectivamente). Además, Cetrelimab estimula los linfocitos T periféricos, aumentando los niveles de citocinas (IFN-γ, IL-2, TNF-α) e inhibiendo el crecimiento tumoral in vivo.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2050478-92-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *